Development of second-generation probiotics as radiation mitigators
Development of second-generation probiotics as radiation mitigators
开发第二代益生菌作为辐射缓解剂
批准号：
10593033
负责人：
CLAUDE ROGERS
金额：
$148.63万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
项目状态：
已结题
起止时间：
2021-03-16 至 2023-03-15
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The University of Pittsburgh and the University of Wisconsin have developed a Lactobacillus reuteri-based cytokine delivery platform (LRC-DP) to mitigate acute gastrointestinal radiation syndrome (GI-ARS) and has licensed this technology to ChromoLogic. ChromoLogic has developed a LRC-DP construct that produces the cytokines IL-22 or IFN-β and plans to test efficacy in animal models of GI-ARS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of second-generation probiotics as radiation mitigators
-
批准号：10807952
-
项目类别：
-
资助金额：$83.26万
-
财政年份：2021
-
负责人：CLAUDE ROGERS
-
依托单位：
海外基金
